Presentation: A Phase 2 Double-Blind Clinical Trial (VZU00025) to Examine the Tolerability, Safety and Effects of CGS-200-0 (Vehicle), CGS-200-1 (1% Capsaicin Topical Liquid) and CGS-200-5 (5% Capsaicin Topical Liquid) on Osteoarthritis Knee Pain (OAKP) (Presented at the 14th Annual Pain Therapeutics Summit on September 21-22, 2020)

Propella Therapeutics, Inc. presented the results of its recently completed Phase 2 double-blind clinical trial (which examined the tolerability, safety and effects of CGS-200-5 (5% capsaicin topical liquid) on osteoarthritis knee pain) at the 14th Annual Pain Therapeutics Summit on September 21-22, 2020.

Presentation: Abiraterone decanoate (AD): Potent and long-acting activity of a novel intramuscular (IM) abiraterone prodrug depot in a castrate monkey model

Propella Therapeutics, Inc. will present “Abiraterone decanoate (AD): Potent and long-acting activity of a novel intramuscular (IM) abiraterone prodrug depot in a castrate monkey model” at the American Society of Clinical Oncology Genitourinary Cancers Symposium on February 11, 2021.

Presentation: A Phase 2 Double-Blind Clinical Trial to Examine the Comparative Effects on Osteoarthritic Knee Pain of CGS-200- 1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin)

View the results of our Phase 2 clinical study of CGS-200-5 presented at the 2019 ACR Annual Meeting View Abstract